ADX71441 / Indivior, Addex - LARVOL DELTA

Positive allosteric modulators of the GABAB receptor: a new class of ligands with therapeutic potential for alcohol use disorder. (PubMed, Alcohol Alcohol) - "These effects closely mirrored those of baclofen; notably, they were associated to remarkably lower levels of tolerance and toxicity. The recent transition of ASP8062 to clinical testing will soon prove whether these highly consistent preclinical data translate to AUD patients."

Journal • Addiction (Opioid and Alcohol)

Sex differences in pathological choice of alcohol over a healthy reward: role of GABAergic transmission in the CeA (Neuroscience 2023) - "We finally assessed whether treatment with the GABAB PAM ADX71441 was able to reduce alcohol choice, as well as other alcohol-related behaviors in both male and females rats. All together, these results support a higher prevalence to develop addiction-like behaviors in male compared to female rats, which aligns with human epidemiological data. Furthermore, they indicate that decreased expression of GAT-3 within CeA is causal for pathological choice behavior in both sexes and that rescuing impaired GABA clearance due to suppressed GAT-3 expression might be a successful therapeutic mechanism in AUD."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry

Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder. (PubMed, Alcohol Alcohol) - "Preclinical studies indicate that GABAB PAMs have a higher therapeutic index than orthosteric agonists, at least in terms of mitigating the sedative effects of GABAB agonism. This predicts that GABAB PAMs have a high translational potential in humans and merit being tested clinically, in particular in patients with severe AUD."

Journal • Addiction (Opioid and Alcohol) • Anesthesia • CNS Disorders • Psychiatry

Research advance of underlying pathogenesis and target therapies in Charcot-Marie-Tooth disease type 1A (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi) - "Other targeting drugs include ascorbic acid, progesterone antagonists, IFB-088, ADX71441, and ACE-083. This review is to sum up the pathogenesis of CMT1A and promising targeting drug therapies for further research."

Journal • Gene Therapies • Genetic Disorders • Pain

Addex and Indivior sign strategic partnership to accelerate development of GABAB PAMs as addiction treatments (GlobeNewswire) - “Addex Therapeutics…announced…the signing of a licensing and collaboration agreement with Indivior PLC…for global development and commercialization of ADX71441 for the treatment of addiction....Under the terms of the agreement, Addex will receive $5 million upfront, $4 million of committed research funding over the next two years, $330 million of potential development..."

Licensing / partnership • Addiction (Opioid and Alcohol) • CNS Disorders

Effect of positive allosteric modulation of GABAB receptors on pathological alcohol choice (Neuroscience 2019) - "...In a first experiment, we therefore evaluated the potential of ADX71441 (3 or 10 mg/kg, I.P), a novel positive allosteric modulator of GABAB receptors that has entered Phase 1 clinical testing, to rescue pathological alcohol choice over high value alternative rewards in male Wistar rats (n=32)...We found that a history of physical alcohol dependence increased the proportion of rats that choose alcohol over an alternative reward to about 45% of the population and therefore assessed the effect of the GABAB PAM on dependence-induced alcohol choice. Together, our results indicate that targeting GABAB receptors is a valid strategy to rescue impaired GABA-clearance in pathological alcohol choice and extend previous data indicating that GABAB PAMs merit being tested clinically as a therapeutic for alcohol addiction."

"Addex $ADXN and Indivior $INDV to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441 https://t.co/wFAP4lGGVp" (@BiotechRadar)